DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV

Information source: Germans Trias i Pujol Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: HIV Infections

Intervention: Nevirapine (Drug); Efavirenz (Drug); Indinavir/ritonavir (Drug); Nelfinavir (Drug); Saquinavir/ritonavir (Drug); Lopinavir/ritonavir (Drug); Atazanavir (Drug); Atazanavir/ritonavir (Drug); Fos-amprenavir/ritonavir (Drug); Tipranavir/ ritonavir (Drug); Darunavir/ritonavir (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Germans Trias i Pujol Hospital

Official(s) and/or principal investigator(s):
Bonaventura Clotet, MD, PhD, Principal Investigator, Affiliation: Lluita contra la Sida Foundation-HIV Unit

Summary

The purpose of this study is to characterise the pharmacokinetic profiles of non-nucleoside analog reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs), and the influence of the individual characteristics on the pharmacokinetic parameters in the Spanish population of HIV-infected subjects.

Clinical Details

Official title: Cross-sectional Study for the Characterisation of the Pharmacokinetic Parameters of Protease Inhibitors and Non-nucleoside Analog Reverse Transcriptase Inhibitors in the Spanish Population of HIV-infected Subjects

Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: The primary endpoint is the plasma concentration of the PI/NNRTI drugs (Ka absorption constant, CI: plasma clearance, Vd: volume of distribution).

Secondary outcome:

Demographic: race, gender, age

Clinical: weight, height, liver/renal impairment, HIV infection stage, tobacco/alcohol consumption

Adverse events

Laboratory: creatinine, albumin, Quick Index, bilirubin, GOT, GPT, GGT, FA, CD4 lymphocyte count, HIV viral load, HBsAg and anti-HCV, alpha acid glycoprotein

Antiretroviral and concomitant treatment, adherence (number of doses omitted in the last two weeks)

Pharmacokinetics: maximum concentration (Cmax), time to maximum concentration (Tmax), plasma concentration at the end of the posology interval (Ctrough), half-life (T1/2), area under the curve (ABC)

Genetic study of polymorphism of CYP3A4 and P-glycoprotein

Detailed description: The antiretrovirals were administered conventionally according to fixed dosage systems, or depending on the weight of the individual in the case of certain agents. However, the plasma levels of antiretrovirals following the administration of a fixed dose present a marked interindividual variability. Moreover, a significant proportion of the patients on treatment with PIs presented plasma levels regarded as suboptimal in previous studies. Moreover, for the correct modification of the dosage of a drug, populational data on its pharmacokinetic behaviour during the dosing interval is required. Only by integrating this information with the specific characteristics of each individual is it possible, using mathematical models, to estimate the effect that a modification of the dosage of the drug would have on its plasma concentration. However, populational data on the pharmacokinetic behaviour of antiretroviral agents are still very limited at this moment, and have not always been obtained in populations similar to the one to which they are to be applied. Thus, knowing the pharmacokinetic behaviour of the antiretroviral agents in our population and the influence of certain individual characteristics on this behaviour may be of great interest, since only in this way will we be able to tailor the dosage of antiretrovirals reliably in our patients.

Eligibility

Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Age higher than 18 years. 2. Documented HIV infection (at least one positive Western-blot) 3. Stable antiretroviral treatment with PI or NNRTI, no changes over the last 4 weeks. 4. Women may not be of fertile age (defined as at least one year from menopause or undergoing any surgical sterilisation technique), or negative pregnancy test. Exclusion Criteria: 1. Subjects on treatment with more than one PI or with combinations of PI and NNRTI (the use of ritonavir in doses below 400 mg BID will not be regarded as a second PI). 2. Treatment with other drugs with known significant pharmacological interactions with the investigational drug over the previous two weeks. 3. Unsuitable adherence to treatment (one or more doses omitted in the last week, or two or more doses omitted in the last two weeks). 4. Presence of clinical findings or a background of gastrointestinal disease or digestive surgery that may interfere in the pharmacokinetics of the medication. 5. Active consumption of alcohol (>50 grams/day) or illegal drugs (except cannabis). 6. In the case of women, pregnancy or breastfeeding. 7. Record or suspicion of inability to cooperate properly

Locations and Contacts

Hospital de la Santa Creu i Sant Pau, Barcelona 08025, Spain

Germans Trias i Pujol Hospital, Badalona, Barcelona 08916, Spain

Hospital de Figueres, Figueras, Barcelona 17600, Spain

FundaciĆ³ Hospital-Asil de Granollers, Granollers, Barcelona 08400, Spain

Hospital de Vic, Vic, Barcelona 08500, Spain

Hospital Universitari Sant Joan de Reus, Reus, Tarragona 43201, Spain

Additional Information

Starting date: January 2005
Last updated: February 22, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017